论文部分内容阅读
本文利用基因重组技术获得的一种人GM-CSF与LIF融合蛋白rhGM-LIF,比较研究了不同浓度rhGM-LIF融合蛋白、rhGM-CSF与rhLIF单独使用及合用的体外抑瘤作用.结果表明,融合蛋白不但能够诱导髓系白血病细胞分化,而且能够抑制其生长,其抑制作用与用药剂量相关,在一定剂量范围内,这种作用显著地高于单个因子和两者合用的效果.值得重视的是,融合蛋白对人肝癌细胞的生长也有明显的抑制作用.实验结果提示,重组的融合蛋白具有潜在的抗肿瘤作用.
In this study, a human GM-CSF and LIF fusion protein rhGM-LIF obtained by gene recombination technology was used to compare the in vitro anti-tumor effect of different concentrations of rhGM-LIF fusion protein, rhGM-CSF and rhLIF, respectively. Fusion protein not only can induce differentiation of myeloid leukemia cells, but also can inhibit its growth. Its inhibitory effect is related to the dosage. Within a certain dose range, this effect is significantly higher than that of a single factor and a combination of both. It is worth noting that Yes, the fusion protein also has a significant inhibitory effect on the growth of human hepatoma cells. The experimental results suggest that the recombinant fusion protein has a potential anti-tumor effect.